Pipeline

Number of Lead Molecules

• 2 recombinant human Interferon-beta variants

Therapeutic area

• Autoimmune Disease

Disease

• Multiple Sclerosis

Clinical Need

• Reduced immunogenicity

Current SOC/Market:

• Rebif®* (Interferon beta-1a); Merck KGaA

• Immunosuppressant

• ~$4B IFN-β market

Supporting Data:

• Precision glycosylated biobetters

• Lower EC50

• Designed for reduced immunogenicity

Status:

_________________________________________________________________________

Number of Lead Molecules

• >500 recombinant human Interferon-beta variants

Therapeutic area

• Autoimmune Disease

Disease

• Multiple Sclerosis

Clinical Need

• Reduced immunogenicity

Current SOC/Market:

• Rebif®* (Interferon beta-1a); Merck KGaA

• Immunosuppressant

• ~$4B IFN-β market

Supporting Data:

• Comparable EC50 to reference drug

Status:

_________________________________________________________________________

Number of Lead Molecules

• 1 Interferon hybrid

Therapeutic area

• Autoimmune Disease

Disease

• Multiple Sclerosis

Clinical Need

• Reduced immunogenicity

Current SOC/Market:

• Rebif®* (Interferon beta-1a); Merck KGaA

• Immunosuppressant

• ~$4B IFN-β market

Supporting Data:

• Hybrid molecule of two genes

• Increased potency

Status:

_________________________________________________________________________

Number of Lead Molecules

• >350 recombinant human Interferon-α2 variants

Therapeutic area

• Cancer, Immunology

Disease

• Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Hepatitis D

Clinical Need

• Susceptible to relapse

Current SOC/Market

• Pegasys®* (peginterferon alfa-2); Genentech

• Blocks relapse

• ~$2B AML market

Supporting Data

• Precision post-translational modifications

• Precision guided disulfide bonds

• Various modifications for improved potency

Status:

_________________________________________________________________________

Number of Lead Molecules

• >1600 recombinant human Interferon-α2 variants

Therapeutic area

• Cancer, Immunology

Disease

• Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Viral Infection

Clinical Need

• Susceptible to relapse

Current SOC/Market

• Pegasys®* (peginterferon alfa-2); Genentech

• Blocks relapse

• ~$2B AML market

Supporting Data

• Precision post-translational modifications

• Precision guided disulfide bonds

• Various modifications for improved potency

Status:

_________________________________________________________________________

Number of Lead Molecules

• 16 recombinant human interferon chimeras

Therapeutic area

• Cancer, Immunology

Disease

• Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Viral Infection

Clinical Need

• Limited efficacy

Current SOC/Market

• Pegasys®* (peginterferon alfa-2); Genentech

• Immune modulator

• ~$3B IFN-alpha2 market

Supporting Data

• Dual gene agonist

• Improved activity compared to IFN-alpha2

Status:

_________________________________________________________________________

*Manufactured drugs are registered trademarks of third parties.

Number of Lead Molecules

• TBD; variant libraries are currently being designed to thousands of unique GLP-1 variants with our powerful cell-based GigaAssay platform—engineered to discover leads with superior potency, enhanced stability, and lower immunogenicity compared to current reference products.

Therapeutic area

• Metabolic disorder

Disease

• Obesity

Clinical Need

• Limited potency

• Immunogenic

• GI-related side effects

Current SOC/Market:

• Semaglutide® * (GLP-1) (Novo Nordisk)

• Improved glycemic control, weight management

• ~$60B GLP-1 market

Supporting Data:

• TBD

Status:

_________________________________________________________________________

Number of Lead Molecules

• TBD; variant libraries are currently being designed to thousands of unique GLP-1 variants with our powerful cell-based GigaAssay platform—engineered to discover leads with similar potency, enhanced stability, and lower immunogenicity compared to current reference products.

Therapeutic area

• Metabolic disorder

Disease

• Obesity

Clinical Need

• Limited potency

• Immunogenic

• GI-related side effects

Current SOC/Market:

• Semaglutide® * (GLP-1) (Novo Nordisk)

• Improved glycemic control, weight management

• ~$60B GLP-1 market

Supporting Data:

• TBD

Status:

_________________________________________________________________________

Number of Lead Molecules

• TBD; variant libraries are currently being designed to unlock thousands of proprietary Incretin (GLP-1, GIP, GCG) variants, rapidly designed and tested in our high-throughput cell-based GigaAssay. We will discover optimized, balanced leads with superior potency across GLP1R, GIPR, and GCGR—delivering enhanced stability and reduced immunogenicity beyond current reference products.

Therapeutic area

• Metabolic disorder

Disease

• Obesity

Clinical Need

• Limited potency

• Immunogenic

• GI-related side effects

Current SOC/Market:

• Retatrutide® * (Incretin tri-agonist) (Eli Lilly & Company)

• Improved glycemic control, weight management

• ~$60B GLP-1 market

Supporting Data:

• TBD

Status:

_________________________________________________________________________

*Manufactured drugs are registered trademarks of third parties.

Number of Drug Resistant Variants

• >100

Therapeutic area

• Cancer

Disease

• HER2+ breast cancer

Clinical Need

• Therapies rotated without biomarker-driven guidance

Current SOC/Market

• HER2+ companion diagnostic

Key points about the significance of HER2

• HER2 (human epidermal growth factor receptor 2) is a protein and gene that plays a critical role in cell growth and division. Its significance is most prominent in breast cancer, where about 20-30% of tumors display HER2 gene amplification or protein overexpression, leading to a subtype known as HER2-positive breast cancer.

• Driver of Aggressive Cancer: When the HER2 gene is amplified, it causes excessive production of the HER2 protein, which in turn triggers uncontrolled cell growth. This results in a particularly aggressive subtype of breast cancer with a tendency for rapid growth and higher risk of recurrence.

• Therapeutic Target: The identification of HER2 as a driver of cancer led to the development of targeted therapies, such as trastuzumab (Herceptin), which have dramatically improved the prognosis for patients with HER2-positive tumors. Effective treatment is closely linked to precise determination of HER2 status.

• Clinical Decision-Making: HER2 status is now routinely tested in breast cancer diagnoses. It guides treatment decisions: tumors positive for HER2 typically benefit from anti-HER2 therapies, while those that are HER2-negative do not.

• Prognosis and Predictive Value: HER2 positivity is associated with greater tumor aggressiveness and used to predict how a patient will respond to specific treatments, including certain chemotherapies and hormonal therapies.

• Molecular Function: HER2 is one of four related receptors (HER1-4) on the cell surface that, when activated (usually by dimerization), trigger intracellular signaling cascades involved in proliferation and survival. Unlike other family members, HER2 does not require a ligand and acts mainly through partnering with other HER family proteins.

Supporting Data

• Expanded HER2 resistance map: 6,000 variants tested -> 250+ resistance mutations identified (vs. 3 known) across 3 key drugs.

Status:

__________________________________________________________________